Gregory Lesinski B PhD

Gregory Lesinski B PhD
Asst ProfessorCollege of Medicinelesinski.1@osu.edu
302B Wiseman Hall 400 W 12th Avenue Columbus Ohio 43210
Phone:614-292-3676Fax:
  • Molecular Carcinogenesis and Chemoprevention

General Research Interest

Immunotherapy, Experimental Therapeutics, Melanoma, Immunomodulatory effects of natural products.

Research Description

Dr. Lesinski’s research is focused on gaining a greater understanding of the interactions between the host immune system and tumor cells. The ultimate goal is to use this knowledge to develop novel therapeutic or chemo-preventative approaches to help patients with cancer, and improve upon existing therapies. Of particular interest are inhibition of the oncogenic STAT3 pathway and maximizing the effect of immune based therapy.

Transinstitutional Work

Dr. Lesinski’s research is focused on gaining a greater understanding of the interactions between the host immune system and tumor cells. The ultimate goal is to use this knowledge to develop novel therapeutic or chemo-preventative approaches to help patients with cancer, and improve upon existing therapies. Dr. Lesinski is interested in how various food-based interventions may modulate inflammation as it relates to disease and health.

Current Publications

  • Louzoun Y, Xue C, Lesinski GB, Friedman AA mathematical model for pancreatic cancer growth and treatments.J Theor Biol 351 74-82 6/21/2014
  • Mace TA, King SA, Ameen Z, Elnaggar O, Young G, Riedl KM, Schwartz SJ, Clinton SK, Knobloch TJ, Weghorst CM, Lesinski GBBioactive compounds or metabolites from black raspberries modulate T lymphocyte proliferation, myeloid cell differentiation and Jak/STAT signaling.Cancer Immunol Immunother in press 6/4/2014
  • Galley JD, Chitchumroonchokchai C, Mace T, Suksamrarn S, Bailey MT, Clinton SK, Lesinski GB, Failla ML, Gutierrez-Orozco F, Thomas-Ahner JM, Berman-Booty LDDietary α-mangostin, a xanthone from mangosteen fruit, exacerbates experimental colitis and promotes dysbiosis in mice.Mol Nutr Food Res 58 1226-38 6/1/2014
  • Monk P, Lam E, Mortazavi A, Kendra K, Lesinski GB, Mace TA, Geyer S, Carson WE, Tahiri S, Bhinder A, Clinton SK, Olencki TA phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.J Immunother 37 180-6 4/1/2014
  • Markowitz J, Luedke EA, Grignol VP, Hade EM, Paul BK, Mundy-Bosse BL, Brooks TR, Dao TV, Kondalasula SV, Lesinski GB, Olencki T, Kendra KL, Carson WEA phase I trial of bortezomib and interferon-α-2b in metastatic melanoma.J Immunother 37 55-62 1/1/2014
  • Mace TA, Collins AL, Wojcik SE, Croce CM, Lesinski GB, Bloomston MHypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells.J Surg Res 184 855-60 10/1/2013
  • Lesinski GBThe potential for targeting the STAT3 pathway as a novel therapy for melanoma.Future Oncol 9 925-7 7/1/2013
  • Mace TA, Bloomston M, Lesinski GBPancreatic cancer-associated stellate cells: A viable target for reducing immunosuppression in the tumor microenvironment.Oncoimmunology 2 e24891 7/1/2013
  • Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GBPancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner.Cancer Res 73 3007-18 5/15/2013
  • Suksamrarn S, Failla ML, Gutierrez-Orozco F, Chitchumroonchokchai C, Lesinski GBα-Mangostin: anti-inflammatory activity and metabolism by human cells.J Agric Food Chem 61 3891-900 4/24/2013
  • Gaudio E, Paduano F, Ngankeu A, Lovat F, Fabbri M, Sun HL, Gasparini P, Efanov A, Peng Y, Zanesi N, Shuaib MA, Rassenti LZ, Kipps TJ, Li C, Aqeilan RI, Lesinski GB, Trapasso F, Croce CMHeat shock protein 70 regulates Tcl1 expression in leukemia and lymphomas.Blood 121 351-9 1/10/2013
  • Nicholas C, Yang J, Peters SB, Bill MA, Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, Grever MR, Young GS, Lesinski GBPRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.).PLoS One 8 e74710 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu